SCHEMBL15280655

SCHEMBL15280655

CCOC(C)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 5/20 0.47
KCNH2 Q12809 2/20 0.47
MEN1 O00255 2/20 0.46
GAA P10253 2/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TSHR P16473 1/20 0.46
CYP2D6 P10635 2/20 0.45
KCNE1 P15382 1/20 0.45
CYP1A2 P05177 2/20 0.42
ALDH1A1 P00352 2/20 0.42
SLC6A2 P23975 3/20 0.42
SLC6A4 P31645 3/20 0.42
SLC6A3 Q01959 2/20 0.42
CASR P41180 1/20 0.41
CHRM2 P08172 2/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21742022 0.85 KCNA5 (0.49) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL28012567 0.82 KCNA5 (0.49) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL15704684 0.82 KCNA5 (0.49) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL21742015 0.81 KCNA5 (0.45) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL7449284 0.79 SLC6A3 (0.48) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL8775532 0.79 KCNA5 (0.46) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL28382973 0.79 MEN1 (0.49) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL21742078 0.79 KCNA5 (0.50) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL16394455 0.79 TSHR (0.41) KCNA5KCNH2MEN1GAAKMT2A
SCHEMBL21742279 0.79 KCNA5 (0.46) KCNA5KCNH2MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240229063-A1 TRANSGENIC CORN EVENT ZM_CSM63715 AND METHODS FOR DETECTION AND USES THEREOF MONSANTO TECHNOLOGY LLC (US) 2024-07-11 US disclosed
WO-2022256806-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. (US) 2022-12-08 WO disclosed
WO-2020254831-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY STORM THERAPEUTICS LTD (GB) 2020-12-24 WO disclosed
EP-3611164-A1 PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT Mitsui Chemicals Agro, Inc. (JP) 2020-02-19 EP disclosed
US-10206931-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-02-19 US disclosed
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 KCNA5 482/4885KCNH2 1260/4885MEN1 4328/4885
US-10206931-B2 Therapeutic compounds and uses thereof EP300, CREBBP, HDAC1 KCNA5 3009/4885KCNH2 3465/4885MEN1 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.